Dr. Yi Jizu has served as a Supervisor since May 2021. He is responsible for overseeing the Group’s operations and financial activities as well as leading the quality center. He joined the Group as a vice president of quality in charge of the Group’s quality center in April 2016 and has served as the senior vice president of quality since December 2019. . Dr. Yi obtained a doctorate in biochemistry from Rutgers University. He was approved as one of the Wuhan High-Tech Development “3551” Talents, and a lifetime honorary member of the Chinese Antibody Society..

Dr. Yi began to work as a research professor in the department of pathology at Mount Sinai School of Medicine in the U.S. in July 2000. , then served as a chief scientist at Becton, Dickinson and Company. He also worked in WuXi Biologics Co., Ltd. (无锡药明生物技术股份有限公司), which is a subsidiary of Wuxi Biologics (Cayman) Inc. (药明生物技术有限公司)

Dr. Yang Bin currently serves as the vice president of the manufacturing center of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).

Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.

Zhang Jing has served as a Supervisor since February 2018. Mr. Zhang joined the Group in January 2011 and successively served as a senior research assistant in the R&D center of the Company, a senior manager of the cell line development department of the Company and a director of the R&D center of the Company. In May 2023, he was promoted as the senior director of the R&D center of the Company. He is responsible for overseeing our operations and financial activities as well as leading the R&D center.

Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics of the Chinese Academy of Science (中国科学院生物物理研究所) from August 2008 to December 2010. Mr. Zhang has also served as a supervisor of Wuhan Huiyou Juyou Enterprise Management Co., Ltd. since June 2022.

Mr. Zhang received a bachelor's degree in biotechnology from the College of Life Sciences, Wuhan University (武汉大学) , and a master's degree in biochemistry and molecular biology from the Graduate School of Chinese Academy of Sciences (中国科学院研究生院) .

Dr. Huang Shaoyi, currently serves as the senior director of the clinical department, who is responsible for the academic support of the Company's clinical projects and developing policies and management processes related to clinical research.

Dr. Huang has extensive experience in clinical research and product development. He served as the deputy director of the medical oncology department of Wuhan YZY Medical Science and Technology Co., Ltd. (武汉友芝友医疗科技股份有限公司) from March 2014 to July 2020, where he was responsible for R&D and clinical work.

He obtained a bachelor's degree in biotechnology in June 2001 and a master's degree in microbiology in December 2004 from Wuhan University (武汉大学), respectively. In August 2013, he obtained a doctorate in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center.